Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
Background. Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/5728946 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554431362629632 |
|---|---|
| author | Masaaki Kondo Kazushi Numata Koji Hara Akito Nozaki Hiroyuki Fukuda Makoto Chuma Shin Maeda Katsuaki Tanaka |
| author_facet | Masaaki Kondo Kazushi Numata Koji Hara Akito Nozaki Hiroyuki Fukuda Makoto Chuma Shin Maeda Katsuaki Tanaka |
| author_sort | Masaaki Kondo |
| collection | DOAJ |
| description | Background. Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to respond to sorafenib treatment. Methods. Among 146 BCLC stage B or C HCC patients treated with sorafenib monotherapy between July 2009 and August 2014, the first radiological progression according to the modified RECIST was identified in 71 patients; factors predicting overall survival (OS) and survival postprogression (SPP) were analyzed in these patients. Results. The median OS and SPP for patients who failed to respond to sorafenib treatment were 10.5 and 6.2 months, respectively, and the SPP was strongly correlated with the OS (r=0.982, P<0.01, and R2=0.965). The independent predictors of OS and SPP were identical. The predictors of SPP were des-gamma-carboxy prothrombin, progression of portal vein thrombosis, and subsequent second-line or additional treatment. Conclusions. SPP is closely associated with OS and might be notable in patients who have failed to respond to initial sorafenib treatment. Furthermore, interventions consisting of other treatment options upon the appearance of progression might prolong OS. |
| format | Article |
| id | doaj-art-7f83c411db5a4fc5a02b8ab62eb63048 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-7f83c411db5a4fc5a02b8ab62eb630482025-02-03T05:51:36ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/57289465728946Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival PostprogressionMasaaki Kondo0Kazushi Numata1Koji Hara2Akito Nozaki3Hiroyuki Fukuda4Makoto Chuma5Shin Maeda6Katsuaki Tanaka7Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanDepartment of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, JapanGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanBackground. Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to respond to sorafenib treatment. Methods. Among 146 BCLC stage B or C HCC patients treated with sorafenib monotherapy between July 2009 and August 2014, the first radiological progression according to the modified RECIST was identified in 71 patients; factors predicting overall survival (OS) and survival postprogression (SPP) were analyzed in these patients. Results. The median OS and SPP for patients who failed to respond to sorafenib treatment were 10.5 and 6.2 months, respectively, and the SPP was strongly correlated with the OS (r=0.982, P<0.01, and R2=0.965). The independent predictors of OS and SPP were identical. The predictors of SPP were des-gamma-carboxy prothrombin, progression of portal vein thrombosis, and subsequent second-line or additional treatment. Conclusions. SPP is closely associated with OS and might be notable in patients who have failed to respond to initial sorafenib treatment. Furthermore, interventions consisting of other treatment options upon the appearance of progression might prolong OS.http://dx.doi.org/10.1155/2017/5728946 |
| spellingShingle | Masaaki Kondo Kazushi Numata Koji Hara Akito Nozaki Hiroyuki Fukuda Makoto Chuma Shin Maeda Katsuaki Tanaka Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression Gastroenterology Research and Practice |
| title | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| title_full | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| title_fullStr | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| title_full_unstemmed | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| title_short | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression |
| title_sort | treatment of advanced hepatocellular carcinoma after failure of sorafenib treatment subsequent or additional treatment interventions contribute to prolonged survival postprogression |
| url | http://dx.doi.org/10.1155/2017/5728946 |
| work_keys_str_mv | AT masaakikondo treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT kazushinumata treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT kojihara treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT akitonozaki treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT hiroyukifukuda treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT makotochuma treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT shinmaeda treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression AT katsuakitanaka treatmentofadvancedhepatocellularcarcinomaafterfailureofsorafenibtreatmentsubsequentoradditionaltreatmentinterventionscontributetoprolongedsurvivalpostprogression |